Harnessing the benefits of endogenous hydrogen sulfide to reduce cardiovascular disease

Abstract

Cardiovascular disease is the leading cause of death in the U.S. While various studies have shown the beneficial impact of exogenous hydrogen sulfide (H2S)‐releasing drugs, few have demon-strated the influence of endogenous H2S production. Modulating the predominant enzymatic sources of H2S—cystathionine‐β‐synthase, cystathionine‐γ‐lyase, and 3‐mercaptopyruvate sul-furtransferase—is an emerging and promising research area. This review frames the discussion of harnessing endogenous H2S within the context of a non‐ischemic form of cardiomyopathy, termed diabetic cardiomyopathy, and heart failure. Also, we examine the current literature around therapeutic interventions, such as intermittent fasting and exercise, that stimulate H2S production.